Lucie Bruijn, Ph.D. joined The ALS Association in January 2001 and is currently the Chief Scientist. Prior to that Dr. Bruijn led a team at Bristol Myers Squibb developing in vitro and in vivo model systems for neurodegenerative disease. Realizing the potential of stem cell therapy for neurodegenerative diseases, her team worked with experts in academia to establish stem cell studies at Bristol Myers Squibb.
At The ALS Association, Dr. Bruijn leads a global ALS research effort, Translational Research to Advance Therapies for ALS (TREAT ALS™) with the goal to move treatment options from “bench to bedside.” She has made it a priority to collaborate with other funding agencies, in particular The National Institutes of Health, The Department of Defense and many other not-for-profit ALS organizations, as well as other foundations focusing on neurodegenerative research. These collaborations ensure that increased dollars are spent on ALS research. She is involved in project development, encouraging partnerships with academia and biotech, and has played a key role in forging collaborations amongst investigators. It is her strong belief that only through collaboration among a wide range of disciplines will we be successful in changing the course of ALS and finding a cure.